Our team of experts brings you cancer-related?news, features, and survivor stories.
Published on: June 18, 2020
The US Food and Drug Administration (FDA) has expanded the approval of the immunotherapy drug pembrolizumab (Keytruda) to include any cancer with a high tumor mutational burden (TMB-H).
Published on: April 29, 2020
The US Food and Drug Administration (FDA) approved a new type of therapy for triple-negative breast cancer that has spread to other parts of the body and hasn¡¯t responded to other treatments.
Published on: April 22, 2020
The US Food and Drug Administration (FDA) approved the first targeted therapy for bile duct cancer. Pemazyre (pemigatinib) is for adults whose cancer has grown after at least one previous chemotherapy treatment and whose tumors have a mutation in the FGFR2 gene.
Published on: April 20, 2020
The US Food and Drug Administration (FDA) approved Jelmyto (mitomycin gel) for a type of urothelial cancer, which is a cancer of the lining of the urinary system.
Published on: January 24, 2020
The US Food and Drug Administration (FDA) has approved Tazverik (tazemetostat) to treat adults and children 16 and older with epithelioid sarcoma, a rare cancer which accounts for less than 1% of all soft tissue sarcomas.
Published on: January 10, 2020
The US Food and Drug Administration (FDA) has approved Ayvakit (avapritinib) to treat people with advanced cases of gastrointestinal stromal tumor (GIST) that have a certain genetic mutation.
Published on: December 20, 2019
The US Food and Drug Administration (FDA) has approved a new type of drug for certain people with bladder cancer.
We fund research breakthroughs that save lives. Your year-end gift helps find new treatments for cancer.